Glibenclamide Induced Linear Immunoglobulin: A Dermatosis (LAD)

Authors

  • Nrithya S. Kumar Department of Pharmacy Practice, P. Rami Reddy College of Pharmacy, Kadapa, AP, India
  • C. Pandu Varaprasad Department of Pharmacy Practice, P. Rami Reddy College of Pharmacy, Kadapa, AP, India
  • Anakha Thyag Department of Pharmacy Practice, P. Rami Reddy College of Pharmacy, Kadapa, AP, India
  • Y. Hrishikesh Reddy Department of Pharmacy Practice, P. Rami Reddy College of Pharmacy, Kadapa, AP, India

Abstract

 

Linear immunoglobulin A dermatitis is a rare autoimmune sub epidermal blistering disorder characterised by continuous deposition of IgA in the basement membrane zone. The disease may be drug related (glibenclamide) or non-drug related (Haematological, rheumatological). This is a rare disease observed in dermatology (IP) department, RIMS, Kadapa. A 50 years old female patient presented lesions on the trunk and purpuric eruptions since 2 months along with oral ulceration and itching. She is a known diabetic since 10 years, and on regular medication with (T. metformin 500 mg+T. glibenclamide 5 mg) etc. The diagnosis was confirmed by histopathology and direct immunofluorescence. So it was confirmed that glibenclamide induced LAD and was reported as an ADR. Based up on the Naranjo’s scale, the assessment was found to be as definite ADR (≥9). The exact pathogenesis of drug induced LAD remains obscure. Further studies are needed to find the mechanism of glibenclamide inducing LAD.

 

Keywords: LAD, dermatosis, autoimmune disease

Cite this Article

Nrithya Kumar S, Pandu Varaprasad C, Anakha Thyag et al. Glibenclamide Induced Linear Immunoglobulin: A Dermatosis (LAD). Research & Reviews: A Journal of Pharmacology. 2016; 6(1): 1–3p.

Downloads

Published

2019-07-23

Issue

Vol. 6 No. 1 (2016)

Section

Case Study

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.